An adaptive randomized clinical trial in interstitial cystitis/bladder pain syndrome evaluating efficacy of ASP3652 and the relationship between disease characteristics and Hunner’s lesions

Houbiers, J. G. A.; Till, J. W. Olivier van; Kaper, Mathilde; Yavuz, Yalçin; Martina, Reynaldo; Cerneus, Dirk; Melis, Joost; Stroosma, Otto B.; Nickel, J. Curtis; Hanno, Philip; Nordling, Jørgen

doi:10.1007/s00345-020-03372-z

Cited by 12 publications

(19 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2). A combination of PEA and polydatin was associated with a significant decrease in pain in the prospective cohort study by Cervigni et al 9 However, an fatty acid amide hydrolase inhibitor did not decrease pain compared with placebo in the RCT by Houbiers et al 10 Of the cohort studies and RCTs, two studies noted adverse events (Table 3). In the Indraccolo et el.…”

Section: Resultsmentioning

confidence: 99%

Medical Cannabis for Gynecologic Pain Conditions

Liang

Gingher

Coleman

2022

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

The endocannabinoid system is involved in pain perception and inflammation. Cannabis contains delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which are cannabinoids that bind to endocannabinoid system receptors. A fatty acid amide called palmitoylethanolamide (PEA) enhances endogenous cannabinoids. Given that use of medical cannabis is increasing, we sought to characterize patterns of cannabis use for gynecologic pain and its effectiveness as an analgesic.DATA SOURCES: We searched PubMed, EMBASE, Scopus, Cochrane, and ClinicalTrials.gov using terms for "woman," "cannabis," and "pain" or "pelvic pain" or "endometriosis" or "bladder pain" or "cancer." The search was restricted to English-language articles published between January 1990 and April 2021 and excluded animal studies. METHODS OF STUDY SELECTION:The initial search yielded 5,189 articles with 3,822 unique citations. Studies were included if they evaluated nonpregnant adult women who used cannabinoids for gynecologic pain conditions (eg, chronic pelvic pain, vulvodynia, endometriosis, interstitial cystitis, malignancy). Study types included were randomized controlled trials (RCTs), cohort studies, and cross-sectional studies. Covidence systematic review software was used.

show abstract

Section: Resultsmentioning

confidence: 99%

Medical Cannabis for Gynecologic Pain Conditions

Liang

Gingher

Coleman

2022

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

“…50,[52][53][54] In the treatment of bladder pain, a FAAH inhibitor, ASP3652, has been tested in women with mild/moderate symptoms of BPS/IC. 55 This clinical trial failed to demonstrate any improvement in pain symptoms and LUTS as compared with placebo. Nevertheless, its use was safe without any psychotropic side-effects that would be expected to occur with the use of cannabinoids.…”

Section: Investigational Treatmentsmentioning

confidence: 89%

Current standard of care in treatment of bladder pain syndrome/interstitial cystitis

Lopez

Mangır

2021

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Bladder pain syndrome/interstitial cystitis (BPS/IC) is a debilitating, systemic pain syndrome with a cardinal symptom of bladder related pain with associated systemic symptoms. It is characterized by an inflammation that partially or completely destroys the mucus membrane and can extend into the muscle layer; however, the etiology and pathogenesis is still enigmatic. It has been suggested that mast cell activation, defects in the glycosaminoglycan layer, non-functional proliferation of bladder epithelial cells, neurogenic inflammation, microvascular abnormalities in the submucosal layer, autoimmunity and infectious causes may cause BPS/IC. Available treatment options include general relaxation techniques, patient education, behavioral treatments, physical therapy, multimodal pain therapy, oral (amitriptyline, cimetidine, hydroxyzine) and intravesical treatments (heparin, lidocaine, hyaluronic acid and chondroitin sulfate), hydrodistension and other more invasive treatments. Available treatments are mostly not based on a high level of evidence. Lack of understanding of disease mechanisms has resulted in lack of targeted therapies on this area and a wealth of empirical approaches with usually inadequate efficacy. The aim of this article is to review the available evidence on the pathophysiological mechanisms of BPS/IC as they relate to available treatment options.

show abstract

“… a Studies [ 149 , 217 , 218 , 219 , 220 ] also reported safety data: in general, the compounds were well‐tolerated by the patients. b Western Ontario and McMaster Universities Osteoarthritis Index.…”

Section: Translation or Lack Thereof Of Faah Inhibitors To The Clinic For The Treatment Of Painmentioning

confidence: 99%

“… a Studies [ 149 , 217 , 218 , 219 , 220 ] also reported safety data: in general, the compounds were well‐tolerated by the patients. …”

Section: Translation or Lack Thereof Of Faah Inhibitors To The Clinic For The Treatment Of Painmentioning

confidence: 99%

See 1 more Smart Citation

The endocannabinoid system – current implications for drug development

Fowler

2021

J Intern Med

View full text Add to dashboard Cite

show abstract

An adaptive randomized clinical trial in interstitial cystitis/bladder pain syndrome evaluating efficacy of ASP3652 and the relationship between disease characteristics and Hunner’s lesions

Cited by 12 publications

References 28 publications

Medical Cannabis for Gynecologic Pain Conditions

Medical Cannabis for Gynecologic Pain Conditions

Current standard of care in treatment of bladder pain syndrome/interstitial cystitis

The endocannabinoid system – current implications for drug development

Contact Info

Product

Resources

About